Compounding Pharmacy · Largo, FL · 503B
BPI Labs Review
BPI Labs is an FDA-registered 503B outsourcing facility and drug manufacturer in Largo, Florida, a subsidiary of Belcher Pharmaceuticals. It historically produced compounded semaglutide and tirzepatide injectables at scale for telehealth brands (notably Hims & Hers). BPI voluntarily halted GLP-1 production around April 2026 as the FDA moved to exclude semaglutide and tirzepatide from the 503B bulk-drug list.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Telehealth Providers Sourcing From This Pharmacy
These telehealth brands are reported to fulfill some or all compounded GLP-1 prescriptions through BPI Labs. Sourcing arrangements can change over time.
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Certifications & Compliance
All sterile compounding pharmacies in the United States are required to follow United States Pharmacopeia General Chapter <797> sterile compounding standards[4], with finished preparations evaluated against USP <71> sterility testing[5] and USP <85> bacterial endotoxin testing[6] as appropriate for the product type.
Drugs Produced
Compounding pharmacies' ability to produce semaglutide or tirzepatide depends on the FDA Drug Shortage List status for each reference product; compounding eligibility can change when a drug moves on or off the shortage list[7].
States Licensed
BPI Labs has not published a state-by-state licensure list. Verify licensure for your state directly with your state board of pharmacy before filling a prescription here.
Regulatory Actions
Weight Loss Rankings Score Breakdown
Scores are independently researched. See our methodology for details.
High confidence · Last verified 2026-07-16 via research · How we verify provider data
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources & methodology — as of July 2026
- 1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
- 3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
- 5.USP General Chapter <71> — Sterility Tests— United States Pharmacopeia.
- 6.USP General Chapter <85> — Bacterial Endotoxins Test— United States Pharmacopeia.
- 7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.